

FINAL PROGRAMME



23rd Annual Conference of the British HIV Association (BHIVA)

4–7 April 2017

Arena and Convention Centre, Liverpool

Including

**Hepatology Highlights for the
Healthcare Specialist**

1830–2030 Tuesday 4 April 2017

www.bhiva.org

#BHIVA2017



Follow us on
social media



Download the BHVA Conferences App



18 CPD Credits
Unique Reference No:
109308

DOLUTEGRAVIR ▼ IS MY CORE

THE **ONLY** INI THAT OFFERS ALL OF THE FOLLOWING:



SUPERIOR EFFICACY

in treatment-naïve patients vs Atripla®, darunavir/r and atazanavir/r (in women)¹⁻³

+



HIGH BARRIER TO RESISTANCE

0 resistance to dolutegravir-based regimens in treatment-naïve trials¹⁻⁵

+



BOOSTER-FREE DOSING

with few clinically significant drug-drug interactions⁵

Build a regimen for your patients with
DOLUTEGRAVIR AT THE CORE.



TRIUMEQ is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40 kg.

Before initiating treatment with abacavir-containing products, HLA-B*5701 status must always be documented. Abacavir should not be used in patients known to carry the HLA-B*5701 allele due to the risk of hypersensitivity reaction.

TIVICAY is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults and adolescents above 12 years of age.

Prescribing Information

Triumeq ▼ dolutegravir 50mg/abacavir 600mg/lamivudine 300mg tablets

See Summary of Product Characteristics before prescribing.

Indication: HIV in over 12 years and >40 kg. Screen for HLA-B*5701 prior to use. Do not use if HLA-B*5701 positive. **Dose:** one tablet once daily with or without food. **Elderly:** Limited data in 65+ yrs. **Creatinine clearance <50ml/min or moderate/severe hepatic impairment:** Not recommended. Monitor closely in mild hepatic impairment. **Contraindications:** Hypersensitivity to any ingredient. Co-administration with dofetilide. **Warnings/precautions:** Both abacavir and dolutegravir are associated with risk of hypersensitivity reactions (HSR). Do not initiate in HLA-B*5701+ or previous suspected abacavir HSR. Stop Triumeq without delay if HSR suspected. Never reintroduce any dolutegravir-or abacavir-containing product after suspected HSR. Risks of immune reactivation syndrome, osteonecrosis, increased weight, lipids, glucose. Monitor LFTs in Hepatitis B/C co-infection. Inconclusive data on relationship between abacavir and MI; minimise all modifiable CV risk factors (e.g. smoking, hypertension, hyperlipidaemia). Not recommended if dolutegravir required b.d. (with etravirine (without boosted PI), efavirenz, nevirapine, rifampicin, boosted tipranavir, carbamazepine, oxcarbazepine, phenytoin, phenobarbital and St John's Wort). Use with cladribine not recommended. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. Caution with metformin: monitor renal function and consider metformin dose adjustment. **Pregnancy/lactation:** Not recommended. Avoid breast-feeding. **Side effects:** See SPC for details. Headache, insomnia, sleep/dream disorders, GI disturbance, fatigue, hypersensitivity, anorexia, depression, dizziness, somnolence, lethargy, malaise, cough, nasal symptoms, rash, pruritus, alopecia, arthralgia, muscle disorders, asthenia, fever, elevations of ALT, AST and CPK, blood dyscrasias, suicidal ideation or suicide attempt, rhabdomyolysis, lactic acidosis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis. **Basic NHS costs:** 30 tablets: £798.16 EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

[POM] S1A

Triumeq is a registered trademark of the ViiV Healthcare Group of Companies
Date of approval: December 2016 Zinc code: UK/TRIM/0037/14(6)

Tivicay ▼ dolutegravir 50mg tablets Prescribing Information

See Summary of Product Characteristics before prescribing.

Indication: HIV in >12 years and >40kg as part of combination therapy. **Dosing:** 50mg once daily with or without food if no proven/suspected integrase resistance. 50mg twice daily with efavirenz, nevirapine, tipranavir/ritonavir, etravirine (without boosted PI), carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St John's Wort or rifampicin. **Adults with proven/suspected integrase resistance:** 50mg twice daily preferably with food. **Elderly:** Limited data in 65+ yrs. Caution in severe hepatic impairment. **Contraindications:** Hypersensitivity to any ingredient. Co-administration with dofetilide. **Warnings/precautions:** Risk of hypersensitivity reactions. Discontinue dolutegravir and other suspect agents immediately if suspected. Risks of osteonecrosis, immune reactivation syndrome. Monitor LFTs in Hepatitis B/C co-infection and ensure effective Hepatitis B therapy. Caution with metformin: monitor renal function and consider metformin dose adjustment. Use with etravirine requires boosted PI or increased dose of dolutegravir. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. **Pregnancy/lactation:** Not recommended. Avoid breast-feeding. **Side effects:** See SPC for full details. Headache, GI disturbance, insomnia, abnormal dreams, depression, dizziness, rash, pruritus, fatigue, elevations of ALT, AST and CPK, hypersensitivity, suicidal ideation or suicide attempt. **Basic NHS costs:** 30 tablets £498.75 EU/1/13/892/001. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT.

[POM] S1A

Tivicay is a registered trademark of the ViiV Healthcare Group of Companies
Date of approval: October 2016 Zinc code: UK/DLG/0055/13(8)

References: 1. Walmsley S et al. J Acquir Immune Defic Syndr. 2015; 70(5):515-519. 2. Molina J-M et al. Lancet HIV. 2015; 2(4):e127-e136. 3. Orrell C et al. Presented at: Annual International AIDS Conference; July 18-22, 2016; Durban, South Africa. Abstract THAB0205LB. 4. Raffi F et al. Lancet Infect Dis. 2013; 13(11):927-935. 5. TIVICAY (dolutegravir) Summary of Product Characteristics. September 2015.

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971, medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.



TRIUMEQ and TIVICAY are registered trademarks of the ViiV Healthcare group of companies.
© 2016 ViiV Healthcare group of companies. All rights reserved.

UK/DGR/0001/17 Date of preparation: January 2017

CONTENTS

BHIVA Committees	4
Programme Summary	5
Programme.....	6–13
Satellite Symposia and Sponsors' Lunchtime Workshops	14,15
Exhibition Floor Plan and Exhibitors	16
Conference Information	17,18
Scholarships and Awards	19
Social Events	20
Plenary Speaker Biographies	21–25
Sponsors and Exhibitors	26

Badges must be worn at all times in order to gain access to the lecture theatre, exhibition and dining areas

LOCATIONS

All locations are in Arena and Convention Centre, Liverpool, unless stated otherwise

Registration	Galleria, Ground Floor
Lecture Theatre	Hall 1A, Upper Level
Exhibition	Hall 2A, Lower Level
Posters	Hall 2A, Lower Level
Lunch and Refreshments	Hall 2A, Lower Level
BHIVA Lunchtime Workshops 1, 5 and FHIVA	Room 4B, Upper Level
BHIVA New Consultants Workshop (Thursday only).....	Room 13, Upper Level
Satellite Symposia	Hall 1A, Upper Level
Sponsors' Workshops	Room 4A, Upper Level
Gilead Sciences Workshop (Thursday only).....	Room 4B, Upper Level
Speakers' Preview Room	Room 10, Upper Level
Sponsors' Rehearsal Room	Room 6, Upper Level
Welcome Reception	Hall 2A, Lower Level
Gala Dinner	The Venue at the Royal Liver Building

18 CPD Credits

Unique reference number: 109308

BHIVA COMMITTEES

BHIVA EXECUTIVE COMMITTEE 2016–17

OFFICERS

Chair

Professor C Orkin Barts Health NHS Trust, London

Vice Chair

Prof C Leen Western General Hospital, Edinburgh

Honorary Secretary

Dr A Sullivan Chelsea and Westminster Hospital, London

Honorary Treasurer

Dr D Churchill Royal Sussex County Hospital, Brighton

MEMBERS

Prof B Angus University of Oxford

Dr D Bradshaw Royal Sussex County Hospital, Brighton

Dr F Burns Royal Free Hospital, London

Dr D Chadwick James Cook University Hospital,
Middlesbrough

Dr M Chaponda University of Liverpool

Mr P Clift BHIVA Community Representative Trustee

Prof Lucy Dorrell University of Oxford

Prof B Gazzard CBE Chelsea and Westminster Hospital, London

Dr Y Gilleece Royal Sussex County Hospital, Brighton

Dr R Kulasegaram St Thomas' Hospital, London

Dr N Mackie St Mary's Hospital, London

Dr I Reeves Homerton University Hospital, London

Prof C Sabin University College London

Dr G Schembri Manchester Centre for Sexual Health

Dr S Taylor Birmingham Heartlands Hospital

Dr L Waters Mortimer Market Centre, London

CONFERENCES SUBCOMMITTEE

Dr L Waters Chair and BHIVA Executive Committee member

Dr I Reeves Vice Chair and BHIVA Executive Committee member

Prof D Back Local Host, BHIVA Annual Conference 2017

Prof B Angus BHIVA Executive Committee member

Dr D Bradshaw New Consultant Doctor's representative and BHIVA Executive Committee member

Dr F Burns BHIVA Executive Committee member

Dr M Chaponda BHIVA Executive Committee member

Dr D Churchill BHIVA Executive Committee member

Mr P Clift BHIVA Executive Committee member and Community Representative

Prof B Gazzard CBE BHIVA Executive Committee member

Dr R Kulasegaram BHIVA Executive Committee member

Prof C Leen BHIVA Executive Committee member

Dr N Mackie BHIVA Executive Committee member

Professor C Orkin BHIVA Executive Committee member

Prof C Sabin BHIVA Education and Scientific Subcommittee Chair

Dr S Taylor BHIVA Executive Committee member

Dr M Tenant-Flowers Invited Representative

Dr E Wilkins Invited Representative

Mrs S Morris Invited Representative

ORAL RESEARCH JUDGING PANEL

Prof S Sabin (Chair) University College London

Dr I Reeves Homerton University Hospital, London

Dr D Churchill Royal Sussex County Hospital, Brighton

Prof C Leen Western General Hospital, Edinburgh

Mr P Clift UK Community Advisory Board

Prof S Khoo University of Liverpool

Dr N Mackie Imperial College Healthcare NHS Trust

POSTER PRESENTATION JUDGING PANEL

Dr M Tenant Flowers (Chair) Retired Consultant in HIV and Sexual Health Medicine

Dr D Bradshaw Brighton and Sussex University Hospitals NHS Trust

Dr R Kulasegaram St Thomas' Hospital, London

Mrs S Morris Western General Hospital, Edinburgh

Mr A Hudson Family Planning Association (FPA)

Dr M Chaponda Royal Liverpool University Hospital

Dr D Chadwick James Cook University Hospital, Middlesbrough

Dr G Schembri Manchester Centre for Sexual Health

PROGRAMME SUMMARY

TUESDAY 4 APRIL 2017

1700–2000	Registration open at Arena and Convention Centre, Liverpool (ACCL)
1830–2030	Hepatology Highlights for the Healthcare Specialist

WEDNESDAY 5 APRIL 2017

0800–1900	Registration and exhibition open at ACCL
0900–0940	BHIVA Review Session
0940–1000	Welcome Address by the Chair of the British HIV Association
1000–1100	ViiV Healthcare UK Scientific Exchange Symposium
1100–1130	Morning Coffee
1130–1230	Janssen Satellite Symposium
1230–1300	BHIVA Invited Lecture 1
1300–1500	Lunch and Poster Presentations
1310–1355	BHIVA Lunchtime Workshops 1 and 2
1355–1455	ViiV Healthcare UK Lunchtime Workshop
1500–1530	MRC Clinical Trials Unit Session
1530–1630	Oral Research Presentations: Session 1
1630–1700	Afternoon Tea
1700–1800	BHIVA Plenary Session 1
1800–1830	BHIVA Keynote Lecture
1830–1930	Welcome Reception

THURSDAY 6 APRIL 2017

0815–1800	Registration and exhibition open at ACCL
0900–1000	Gilead Sciences Satellite Symposium
1000–1100	BHIVA Plenary Session 2 in collaboration with European AIDS Clinical Society (EACS)
1100–1130	Morning Coffee
1130–1300	Oral Research Presentations: Session 2
1300–1500	Lunch and Poster Presentations
1310–1355	BHIVA Lunchtime Workshops 3 and 4
1355–1455	Gilead Sciences Lunchtime Workshop
1355–1455	MSD Lunchtime Workshop
1500–1630	Oral Research Presentations: Session 3
1630–1700	Afternoon Tea
1700–1830	BHIVA Invited Lectures 2, 3 and 4
1945	Gala Dinner: The Venue at the Royal Liver Building

FRIDAY 7 APRIL 2017

0830–1430	Registration and Exhibition open at ACCL
0900–1000	HIV Drug Interactions Website Session
1000–1030	BHIVA Audit Session
1030–1100	Morning Coffee
1100–1200	Oral Research Presentations: Session 4
1200–1230	Oral Poster Presentations
1230–1430	Lunch and Poster Presentations
1240–1325	BHIVA Lunchtime Workshop 5
1240–1325	FHIVA Lunchtime Workshop
1325–1425	Gilead Sciences Lunchtime Workshop
1430–1445	BHIVA Prizes and Awards Ceremony
1445–1515	BHIVA Invited Lecture 5
1515–1615	BHIVA Plenary Session 3
1615	Close by the Chair of the British HIV Association

ANNUAL CONFERENCE PROGRAMME

TUESDAY 4 APRIL 2017

1700–2000

Registration and welcome refreshments

◀ All sessions will be held in Hall 1A unless otherwise stated ▶

1830–2030

Hepatology Highlights for the Healthcare Specialist

1830–1835

Introduction

Dr Ranjababu Kulasegaram

St. Thomas' Hospital, London

Dr Andrew Ustianowski

North Manchester General Hospital

1835–1905

RAS testing in HCV - when and how?

Dr Emma Thomson

University of Glasgow

1905–1940

End-stage liver disease: a case discussion

Professor Clifford Leen

Western General Hospital, Edinburgh

1940–2010

New targets, potential new therapies for HBV

Dr Andrew Ustianowski

North Manchester General Hospital

2010–2030

Panel discussion: the future of viral hepatitis care in the UK

Supported by

abbvie



GILEAD



MSD

Sponsors do not have any involvement in speaker selection or content of this session.

WEDNESDAY 5 APRIL 2017

0800–1900

Registration and exhibition open at Arena and Convention Centre, Liverpool (ACCL)

◀ All sessions will be held in Hall 1A unless otherwise stated ▶

0900–0940

BHIVA Review Session

Chair: Dr Laura Waters

Mortimer Market Centre, London

Translating recent research into clinical practice

Dr Matthew Page

Birmingham Heartlands Hospital

Dr Steve Taylor

Birmingham Heartlands Hospital

0940–1000

Welcome Address by the Chair of the British HIV Association

Professor Chloe Orkin

Barts Health NHS Trust, London

1000–1100

ViiV Healthcare UK Scientific Exchange Symposium (please see pages 14–15 for further information)

1100–1130

Morning Coffee

1130–1230

Janssen Satellite Symposium (please see pages 14–15 for further information)

ANNUAL CONFERENCE PROGRAMME

WEDNESDAY 5 APRIL 2017

◀ All sessions will be held in Hall 1A unless otherwise stated ▶

1230–1300

BHIVA Invited Lecture 1

Chair: Professor Clifford Leen

Western General Hospital, Edinburgh

Travellers with HIV: what to take, what will you bring back?

Dr Philip Gothard

University College London Hospitals NHS Foundation Trust

1300–1500

Lunch and Poster Presentations

1310–1355

BHIVA Lunchtime Workshop 1

Clinico-pathological case presentations

Chairs: Dr Ula Mahadeva

Guy's and St Thomas' Hospital NHS Foundation Trust, London

Dr Melinda Tenant Flowers

Retired Consultant in HIV and Sexual Health Medicine

A lump in the neck

Dr Emily Clarke

Solent NHS Trust, Portsmouth

A fortitudinous diagnosis in an HIV- positive man

Dr David Connell

Royal Free London NHS Foundation Trust

Light at the end of the tunnel

Dr Owen Seddon

University Hospital of Wales, Cardiff

1310–1355

BHIVA Lunchtime Workshop 2, Room 4B, Upper Level

Chair: Mr Paul Clift

UK Community Advisory Board (UK-CAB)

UK-CAB Workshop: NHS sustainability and transformation plans: financial restrictions and their effects on HIV clinical care

Professor Simon Barton

Chelsea and Westminster Hospital, London

Dr JS Bamrah

British Medical Association

1355–1455

ViiV Healthcare UK Lunchtime Workshop Room 4A, Upper Level (please see pages 14-15 for further information)

1500–1530

MRC Clinical Trials Unit Session

Chair: Dr Mas Chaponda

Royal Liverpool University Hospital

The motion: This house believes that efavirenz should remain as an option to treat HIV in the UK

For the motion: Dr Sarah Pett

MRC Clinical Trials Unit, London

Against the motion: Dr Alejandro Arenas-Pinto

MRC Clinical Trials Unit, London

1530–1630

Oral Research Presentations: Session 1: Antiretroviral Therapy

Chairs: Dr Angela Obasi

Liverpool School of Tropical Medicine

Dr Ian Williams

Mortimer Market Centre, London

ANNUAL CONFERENCE PROGRAMME

WEDNESDAY 5 APRIL 2017

1530–1540 Abstract O1

Safety of switching raltegravir 400mg twice daily to raltegravir 800mg once daily in virologically suppressed patients

Miss Amy Moore, Chelsea and Westminster Hospital NHS Foundation Trust, London

1540–1550 Abstract O2

Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir

Dr Joseph Custodio, Gilead Sciences Ltd

1550–1600 Abstract O3

Integrase inhibitor resistance in HIV-positive patients undergoing routine testing: frequency and clinical implications

Dr Daniela Kirwan, Public Health England

1600–1610 Abstract O4

Timing of detection of treatment-emergent resistance during rebound viraemia

Dr Nicola Mackie, Imperial College Healthcare NHS Trust, London

1610–1620 Abstract O5

Patient's perceptions of switching from Atripla to generic Truvada and efavirenz

Dr Hardeep Kang, Blackpool Teaching Hospitals NHS Foundation Trust

1620–1630 Abstract O6

The next generation update

Miss Venita Hardweir, Brighton and Sussex University Hospitals NHS Trust

1630–1700

Afternoon Tea

1700–1800

BHIVA Plenary Session 1

HIV training and the launch of the new internal medicine curriculum

Chairs: Professor Chloe Orkin

Barts Health NHS Trust, London

Professor Caroline Sabin

University College London

Changes to postgraduate specialty training and the introduction of the new internal medicine curriculum

Dr Alastair Miller

Joint Royal Colleges of Physicians Training Board

HIV training in the dually accredited Internal Medicine and GUM curriculum

Dr Rak Nandwani

NHS Greater Glasgow and Clyde

The impact of the changes on common infection training

Professor Martin Wiselka

University Hospitals of Leicester NHS Trust

How those in training will be affected and what can be done to prepare for the future

Dr Emily Lord

Oxford University Hospitals NHS Foundation Trust

Panel discussion

1800–1830

BHIVA Keynote Lecture

Chair: Professor Brian Gazzard CBE

Chelsea and Westminster Hospital, London

Towards elimination of HIV amongst gay and bisexual men in the United Kingdom

Dr Valerie Delpech

Public Health England

Dr Monica Desai

Public Health England

1830–1930

Welcome Reception Hall 2A, lower level (see page 20 for further details)
Arena and Convention Centre, Liverpool (ACCL)

ANNUAL CONFERENCE PROGRAMME

THURSDAY 6 APRIL 2017

0815–1800

Registration and exhibition open at Arena and Convention Centre, Liverpool (ACCL)

◀ All sessions will be held in Hall 1A unless otherwise stated ▶

0900–1000

Gilead Sciences Satellite Symposium (please see pages 14-15 for further information)

1000–1100

BHIVA Plenary Session 2

In collaboration with the European AIDS Clinical Society (EACS)

Chairs: Dr Sanjay Bhagani

Royal Free London NHS Foundation Trust

Dr Ranjababu Kulasegaram

St Thomas' Hospital, London

HIV/hepatitis co-infection

Dr Christoph Boesecke

University of Bonn, Germany

Looking beyond HIV: the factors to consider with an ageing population

Dr Lene Ryom

Centre of Excellence for Health, Immunity and Infections, Copenhagen, Denmark

1100–1130

Morning Coffee

1130–1300

Oral Research Presentations: Session 2: Testing and Early Infection

Chairs: Professor Lucy Dorrell

University of Oxford

Mr Alastair Hudson

Family Planning Association (FPA)

1130–1140 Abstract O7

HIV self-testing: feasibility and acceptability of a large scale national service.

Dr Michael Brady, Terrence Higgins Trust

1140–1150 Abstract O8

Routine blood-borne virus testing for HIV, hepatitis B and hepatitis C in the emergency department: the 'new normal'?

Dr Sarah Parry, Royal London Hospital

1150–1200 Abstract O9

HIV testing in a London emergency department: the first 21 weeks

Dr Hannah Alexander, King's College Hospital NHS Foundation Trust, London

1200–1210 Abstract O10

Source of HIV-1 drug-resistant minority variants in people who are recently infected

Dr Jean Mbisa, Public Health England

1210–1220 Abstract O11

Impact of ART in primary HIV infection on T cell immune exhaustion in gut-associated lymphoid tissue: implications for HIV persistence

Dr John Thornhill, Imperial College Healthcare NHS Trust, London

1220–1230 Abstract O12

The impact of immunoglobulin in acute HIV Infection on the HIV reservoir: a randomized controlled trial

Dr Olubanke Davies, Guy's and St Thomas' NHS Foundation Trust, London

1230–1240 Abstract O13

Engineered affinity-enhanced immune-mobilising monoclonal T cell receptors (ImmTAVs) for HIV cure

Miss Zoë Wallace, University of Oxford

1240–1250 Abstract O14

Rapid initiation of antiretroviral treatment in newly diagnosed HIV: experience of a central London clinic

Dr Gary Whitlock, Chelsea and Westminster Hospital NHS Foundation Trust, London

ANNUAL CONFERENCE PROGRAMME

THURSDAY 6 APRIL 2017

◀ All sessions will be held in Hall 1A unless otherwise stated ▶

	<p>1250–1300 Abstract O15 A time-updated continuum of care in a UK cohort <i>Ms Sophie Jose, University College London</i></p>
1300–1500	Lunch and Poster Presentations
1310–1355	<p>BHIVA Lunchtime Workshop 3 Pregnancy and breastfeeding case presentations Chairs: Dr Margaret Kingston <i>Manchester Royal Infirmary</i></p> <p>Dr Gareth Tudor-Williams <i>Imperial College Healthcare NHS Trust, London</i></p> <p>HIV test? No thank you Dr Natasha Astill <i>Leeds Teaching Hospital NHS Trust</i></p> <p>Shining a torch on prophylaxis in pregnancy Dr Subathira Dakshina <i>Barts Health NHS Trust, London</i></p> <p>Can we use dolutegravir BD in pregnancy? Dr Rebecca Thomson Glover <i>Royal Liverpool University Hospital</i></p>
1310–1355	<p>BHIVA Lunchtime Workshop 4, Room 13, Upper Level New consultants workshop Chairs: Dr Daniel Bradshaw <i>Royal Sussex County Hospital, Brighton</i></p> <p>Dr Gabriel Schembri <i>Manchester Centre for Sexual Health</i></p> <p>How to get sued in HIV medicine Dr Matthew Phillips <i>Cumbria Partnership NHS Foundation Trust</i></p> <p>How to be a great educational supervisor Dr Rak Nandwani <i>NHS Greater Glasgow and Clyde</i></p>
1355–1455	Gilead Sciences Lunchtime Workshop, Room 4B, Upper Level (please see pages 14–15 for further information)
1355–1455	MSD Lunchtime Workshop, Room 4A, Upper Level (please see pages 14–15 for further information)
1500–1630	<p>Oral Research Presentations: Session 3: Toxicities and Co-morbidities Chairs: Dr David Chadwick <i>James Cook University Hospital, Middlesbrough</i></p> <p>Dr Mark Lawton <i>Royal Liverpool and Broadgreen University Hospitals NHS Trust</i></p> <p>1500–1510 Abstract O16 Suicide among people diagnosed with HIV in England and Wales compared to the general population <i>Miss Sara Croxford, Public Health England</i></p> <p>1510–1520 Abstract O17 The effect of HIV co-morbidity on mental health outcomes among people accessing services for serious mental illness (SMI) in South London <i>Dr Cat Kirby, King's College Hospital NHS Foundation Trust, London</i></p>

ANNUAL CONFERENCE PROGRAMME

THURSDAY 6 APRIL 2017

1520–1530 Abstract O18

Clinical correlates of cognitive function in people living with HIV (PLHIV): a cross-sectional study
Dr Olubanke Davies, Guy's and St Thomas' NHS Foundation Trust, London

1530–1540 Abstract O19

TDF associated renal tubular dysfunction: non-invasive assessment of mitochondrial injury
Mr Ryan Samuels, Newcastle University

1540–1550 Abstract O20

Plasma Epstein–Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma
Prof Mark Bower, Chelsea and Westminster Hospital NHS Foundation Trust, London

1550–1600 Abstract O21

Impact of HTLV-1 co-infection on T-cells in patients with fully suppressed HIV infection: an open, single centre, cross-sectional study
Prof Graham Taylor, Imperial College Healthcare NHS Trust, London

1600–1610 Abstract O22

Clinical research cerebral MRI findings in HIV positive subjects and appropriate controls
Miss Srishti Chhabra, Imperial College London

1610–1620 Abstract O23

The role of hepatitis C core antigen(HCV-cAg) testing in the era of hepatitis C direct-acting antivirals (DAAs)
Mr Joel Paparello, Guy's & St Thomas' Hospital NHS Foundation Trust

1620–1630 Abstract O24

Acute hepatitis C infection in lower risk MSM: an evolving picture
Dr Laura Midgley, Mortimer Market Centre, London

1630–1700

Afternoon Tea

1700–1730

BHIVA Invited Lecture 2

Chair: Dr Adrian Palfreeman
Leicester Royal Infirmary

Generics: the facts

Dr Andrew Hill
University of Liverpool

This lecture is supported by an educational grant from Mylan. Mylan have had no involvement in the content or participants of this lecture.

1730–1800

BHIVA Invited Lecture 3

Chair: Dr Iain Reeves
Homerton University Hospital, London

The latest in STI diagnostics

Dr Suneeta Soni
Brighton and Sussex University Hospitals NHS Trust

1800–1830

BHIVA Invited Lecture 4

Chair: Professor Lucy Dorrell
University of Oxford

An overview of basic science discoveries that will impact upon clinical practice

Dr John Frater
University of Oxford

1945

Gala Dinner (see page 20 for further details)
The Venue at the Royal Liver Building

ANNUAL CONFERENCE PROGRAMME

FRIDAY 7 APRIL 2017

0830–1430

Registration and exhibition open at Arena and Convention Centre, Liverpool (ACCL)

◀ All sessions will be held in Hall 1A unless otherwise stated ▶

0900–1000

HIV Drug Interactions Website Session

Chair: Dr Steve Taylor

Birmingham Heartlands Hospital

Professor Saye Khoo

University of Liverpool

Dr Nneka Nwokolo

Chelsea and Westminster Hospital, London

Panellist: Professor David Back

University of Liverpool

1000–1030

BHIVA Audit Session

Chair: Dr Hilary Curtis

BHIVA Audit Co-ordinator

BHIVA Standards of Care: an interactive session

Dr David Chadwick

James Cook University Hospital

Dr Ann Sullivan

Chelsea and Westminster Hospital NHS Foundation Trust

1030–1100

Morning Coffee

1100–1200

Oral Research Presentations: Session 4: Living with HIV

Chairs: Professor Jane Anderson CBE

Homerton University Hospital

Mrs Sheila Morris

Western General Hospital, Edinburgh

1100–1110 Abstract O25

Experiences of HIV disclosure and stigma in the dental setting: findings from the people living with HIV Stigma Survey 2015

Mr Alastair Hudson, Family Planning Association (FPA)

1110–1120 Abstract O26

Perceptions of HIV within the general public

Mr Alex Sparrowhawk, Terrence Higgins Trust

1120–1130 Abstract O27

Affording formula: HIV - positive women's experiences of the financial strain of infant formula feeding in the UK

Ms Bianca Karpf, Body and Soul

1130–1140 Abstract O28

Does the introduction of a dedicated postnatal contraception clinic improve reproductive choices for HIV - positive women?

Dr Emily Mabonga, King's College Hospital NHS Foundation Trust, London

1140–1150 Abstract O29

Age related viral suppression in adolescents living with perinatally acquired HIV Infection

Ms Sophie Raghunanan, Imperial College Healthcare NHS Trust, London

1150–1200 Abstract O30

Assessing the clinical complexity of a national cohort of adults accessing HIV outpatient care

Mr Peter Kirwan, Public Health England

1200–1230

Oral Poster Presentations

Chairs: Professor Caroline Sabin

University College London

Dr Melinda Tenant Flowers

Retired Consultant in HIV and Sexual Health Medicine

ANNUAL CONFERENCE PROGRAMME

FRIDAY 7 APRIL 2017

1230–1430

Lunch and Poster Presentations

1240–1325

BHIVA Lunchtime Workshop 5

Low level viraemia case presentations

Chairs: Professor Anna Marie Geretti

University of Liverpool

Dr Nicola Mackie

Imperial College Healthcare NHS Trust, London

Thirteen, lucky for some: lessons learned from managing long-term low-level viraemia

Dr Lucy Rivett

Addenbrooke's Hospital, Cambridge

The perils of boosted Hepatitis C treatment

Dr Nilani Uthayakumar

Mortimer Market Centre, London

1240–1325

FHIVA Lunchtime Workshop, Room 4B, Upper Level

Chair: Dr Caroline Foster

Imperial College Healthcare NHS Trust, London

Solving the problems of transition: a multidisciplinary virtual clinic

Panellists:

Adult clinician: Dr Claire Robertson *Birmingham Heartlands Hospital*

Nurse: Miss Michelle Croston *North Manchester General Hospital*

Pharmacist: Mrs Kate Gandhi *Birmingham Heartlands Hospital*

Psychologist: Ms Sarah Rutter *North Manchester General Hospital*

1325–1425

Gilead Sciences Lunchtime Workshop, Room 4A, Upper Level (please see pages 14–15 for further information)

1430–1445

BHIVA Prizes and Awards Ceremony

Chairs: Professor Chloe Orkin

Barts Health NHS Trust, London

Dr Laura Waters

Mortimer Market Centre, London

1445–1515

BHIVA Invited Lecture 5

Chair: Dr Yvonne Gilleece

Brighton and Sussex University Hospitals NHS Trust

Neurocognitive symptoms in people with HIV

Dr Tristan Barber

Chelsea and Westminster Hospital, London

Dr Paul Holmes

St Thomas' Hospital, London

1515–1615

BHIVA Plenary Session 3

Chairs: Dr Duncan Churchill

Brighton and Sussex University Hospitals NHS Trust

Dr Iain Reeves

Homerton University Hospital, London

Mental health among people with HIV: insights from the ASTRA Study

Dr Fiona Lampe

University College London

Clinical assessment

Dr John Green

Imperial College Healthcare NHS Trust, London

Mental health of healthcare workers

Mr Richard Jones

Riverside Medical Practice, London

1615

Close by the Chair of the British HIV Association

SATELLITE SYMPOSIA AND SPONSORS' LUNCHTIME WORKSHOPS

WEDNESDAY 5 APRIL 2017

All Satellite Symposia will be held in Hall 1A, Upper Level

1000–1100

ViiV Healthcare UK Scientific Exchange Symposium

Current ART paradigms: design or coincidence?

Chair: Dr Andrew Ustianowski

Consultant in Infectious Diseases, North Manchester General Hospital

Discussants: Dr Amanda Clarke

Consultant in HIV/GUM & Clinical Trials, Royal Sussex County Hospital, Brighton

Professor Saye Khoo

Honorary Consultant in Infectious Diseases, Royal Liverpool University Hospital

1130–1230

Janssen Satellite Symposium

Cases from the MDT: managing the mental health of people living with HIV

Chair: Professor Chloe Orkin

Consultant in HIV Medicine, Barts Health NHS Trust, London

Speakers: Dr Sarah Parry

Sexual Health and HIV Registrar, Barts Health NHS Trust, London

Dr Hugh Selsick

Consultant Psychiatrist, University College London Hospitals NHS Foundation Trust

Ms Michelle Croston

Clinical Nurse Specialist, North Manchester General Hospital

Ms Fiona Marra

Senior HIV/HCV Pharmacist, Gartnavel Hospital, Glasgow

1355–1455

ViiV Healthcare UK Lunchtime Workshop, Room 4A, Upper Level

Undetectable: End of Story? The patients' response

Chair: Mr Robert Fieldhouse

BASELINE

Speakers: Miss Angelina Namiba

Salamander Trust

Mr Brad Hepburn

Positively UK

Mr Bryan Dramiga

Children's HIV Association

Mr Tom Hayes

Beyondpositive

Ms Samantha Dawson

Body Positive, Dorset

THURSDAY 6 APRIL 2017

0900–1000

Gilead Sciences Satellite Symposium

Decoding policy: the definite guide to relativity

Chair: Dr Laura Waters

Mortimer Market Centre, London

Faculty: Dr Mas Chaponda

Royal Liverpool University Hospital

Professor Karen Walker-Bone

Brighton and Sussex Medical School

Professor Bruce Hendry

King's College, London

SATELLITE SYMPOSIA AND SPONSORS' LUNCHTIME WORKSHOPS

THURSDAY 6 APRIL 2017

1355–1455

Gilead Sciences Lunchtime Workshop, Room 4B, Upper Level

Mind the gap: addressing the unmet need in mood and sleep disturbance in people living with HIV

Faculty: Dr Lewis Haddow
University College London

Dr Louise Breuer
Mortimer Market Centre, London

Ms Sophie Strachan
The Sophia Forum

1355–1455

MSD Lunchtime Workshop, Room 4A, Upper Level

Trans people, HIV and hep C: key priorities, key populations

Faculty: Dr Tristan Barber
Consultant Physician, Chelsea and Westminster Hospital, London

Dr Laura Mitchell
Consultant Physician, The Laurels, Gender Identity Clinic, Exeter

Ms Michelle Ross
CliniQ, 56 Dean Street, London

Mr Aedan Wolton
CliniQ, 56 Dean Street, London

FRIDAY 7 APRIL 2017

1325–1425

Gilead Sciences Lunchtime Workshop, Room 4A, Upper Level

A patient-given right: insights into shared decision making in a changing NHS landscape

Chair: Mr Chris Woolls
Cara Trust

Speakers: Ms Beatrice Osoro
Positively UK
Mr Damian Kelly
European AIDS Treatment Group


Mr Denis Onyango
Africa Advocacy Foundation

Ms Sarah Radcliffe
National AIDS Trust

Dr Jonathan Cartledge
Mortimer Market Centre, London

EXHIBITION FLOOR PLAN AND EXHIBITORS

Arena and Convention Centre Liverpool



EXHIBITORS

- | | |
|---------------------------------|--|
| 1 MSD Ltd | 15 Dietitians in HIV/AIDS
Rehabilitation in HIV Association |
| 2 ViiV Healthcare UK | 16 NAM |
| 3 ViiV Healthcare UK Medical | 17 The Sophia Forum |
| 4 Positively UK | 18 Gilead Science Ltd |
| 5 African Health Policy Network | 19 HIV i-Base / UK Community Advisory Board |
| 6 The Sussex Beacon | 20 Terrence Higgins Trust |
| 7 Sahir House | 21 Gilead Science Ltd OSS Team |
| 8 HIV Trainee's Club | 22 Oxford Immunotec |
| 9 Body and Soul | 23 Saving Lives |
| 10 Children's HIV Association | 24 Cepheid |
| 11 Public Health England | 25 George House Trust |
| 12 Kora Healthcare | 26 Janssen |
| 13 Mildmay Hospital | 27 National AIDS Trust |
| 14 Idox Health | 28 HIV Pharmacy Association |

CONFERENCE INFORMATION

Arena and Convention Centre, Liverpool
Kings Dock · Liverpool Waterfront · Liverpool · L3 4FP
Telephone: +44 (0)151 475 8888 · www.accliverpool.com

Registration

Registration includes access to all scientific sessions, including satellite symposia, the exhibition area, refreshments and lunch for the days specified in your registration acknowledgement correspondence.

Delegate badges

Badges must be worn at all times to gain access to the lecture theatre, catering and exhibition areas.

Accompanying persons: *pre-booked and paid only*

Accompanying persons' fees include attendance at the Welcome Reception and Gala Dinner. Each event is individually priced. These tickets must have been requested and paid for in advance of the conference. Please note that these fees do not cover attendance at the scientific sessions, exhibition or catering areas of the conference.

BHIVA Lunchtime Workshops

One workshop per day will be held in the lecture theatre for which places are not restricted. For BHIVA workshops in other locations places are limited to 80 persons, with the exception of the New Consultants workshop which is limited to 50 delegates. Doors will open 15 minutes prior to these workshops and places are available on a first-come, first-served basis. Each workshop will begin promptly. No lunch packs will be provided for delegates attending workshops, lunch will be available in the Exhibition Hall for the full duration of the lunch period.

Hepatology highlights for the Healthcare Specialist

BHIVA will be holding a Hepatology Highlights session for the HIV Physician from 1830 to 2030 on Tuesday 4 April 2017. Light refreshments will be provided prior to this meeting.

Continuing Professional Development (CPD)

Medical staff in career grade posts who are enrolled with one of the Royal Medical Colleges for Continuing Professional Development will be entitled to receive CPD credits at the rate of one CPD credit per conference hour (exclusive of travel, refreshments, pharmaceutical-supported sessions and social events). The unique reference code for the conference is 109308. The entire conference has been allocated 18 CPD credits. Please be advised that the attendance list of the conference will be forwarded to the Royal College of Physicians upon request.

Social events

There are two social events: a Welcome Reception (Wednesday) to be held at ACC Liverpool and a Gala Dinner (Thursday) to be held at The Venue at the Royal Liver Building. Tickets are required to gain entry to the Gala Dinner. Please refer to page 20 of this programme for full details of the social events. If you have reserved a ticket but find that you cannot attend, please let the Conference Organiser know as soon as possible and return your ticket to the Registration Desk at your earliest convenience.

Poster presentations

All poster boards will be numbered and poster presenters should use the board displaying the number allocated to their poster. The poster judges will review the posters and subsequently select 15 posters to be highly commended, out of which six will be presented as part of the Poster Presentations session at 1200–1230 on Friday 7 April. Poster presenters are required to prepare a few slides prior to the conference to highlight the main points of their poster. We would encourage all poster presenters to check the Registration notice board at 1830 on Thursday 6 April to see whether they have been selected. The BHIVA Ian Williams Best Poster prize will be awarded at the Prizes and Awards Ceremony on Friday 7 April at 1430–1445.

CONFERENCE INFORMATION

Oral research presentations

Oral research presenters are reminded to ensure they bring their oral research presentation slides to the conference in addition to sending them to the Conference Organisers in advance. Any slides must be passed to the audio-visual technicians in the Speakers' Preview Room located in the Room 10, Upper Level in good time for their session (minimum 3 hours in advance). Oral research presenters may make use of the Speakers' Preview Room to review their slides prior to presentation. The BHIVA Margaret Johnson Best Oral Presentation prize will be awarded at the Prizes and Awards Ceremony on Friday 7 April at 1430–1445.

Accommodation

Please note that the registration fee does not include accommodation. If you have not already arranged accommodation you can do so by referring to the conference website for further details.

WiFi

Free WiFi access is available throughout the conference venue.

Cloakroom

A manned cloakroom is available onsite at ACC Liverpool. All belongings are left at the owner's risk. The British HIV Association does not accept responsibility for the loss of, or damage to, delegates' personal property stored in the cloakroom area.

Exhibition

The exhibition represents an integral element of the conference, providing participants with an excellent platform for networking as well as an opportunity to gain further insight into cutting-edge technology, the latest healthcare solutions, and services within the field of HIV and GU medicine. Entrance to the exhibition hall is free for all registered delegates.

Filming and photography

Please note that all sessions held in the lecture theatre (Hall 1A) will be filmed and uploaded to the BHIVA website following the event. In addition, some still photography will take place at the conference. This will include general coverage of registration, exhibition and workshop areas, as well as conference social events. This material may be published in BHIVA publications or on the BHIVA website and on BHIVA's social media pages.

BHIVA Conferences App



BHIVA have developed a conference app which is downloadable from App Store for iPhone users or Playstore for Android devices. The app will provide users with the following facilities:

- Test the Chair (note all questions will be moderated).
- Voting for the three BHIVA case presentation workshops.
- Information on the conference programme speakers, sponsors and exhibitors.
- Ability to complete the Conference Evaluation Questionnaire via the app.

Social Media

Follow BHIVA on social media.



BritishHIVAssociation



British HIV Association



@BritishHIVAssoc

www.bhiva.org

#BHIVA2017

SCHOLARSHIPS AND AWARDS

The BHIVA Margaret Johnson Best Oral Research Presentation

This prize will be awarded to the presenter of the best oral research presentation during the conference. All oral research presentations will be judged by a BHIVA-appointed oral research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 7 April.

The BHIVA Ian Williams Best Poster Presentation

This prize will be awarded to the presenter of the best poster research presentation during the conference. All poster research presentations will be judged by a BHIVA-appointed poster research judging panel, and to be eligible for this prize the presenter must be of junior grade (sub-consultant or equivalent). The prize will be presented at the Prizes and Awards Ceremony on Friday 7 April.

The BHIVA Best Case Presentation

A prize will be awarded to the presenter of the best case presentation as part of the BHIVA Lunchtime Clinico-pathological, Pregnancy and breastfeeding and Low-level viraemia case presentations sessions. The prizes will be presented at the Prizes and Awards Ceremony on Friday 7 April.

Commended Oral Presentations

Up to three awards will be presented in recognition of the best oral research presentations during the conference. To be eligible for these prizes the presenter must be of junior grade (sub-consultant or equivalent). All oral presentations will be judged by a BHIVA-appointed oral research judging panel. The awards will be acknowledged during the Prizes and Awards Ceremony on Friday 7 April.

Commended Poster Presentations

Up to 15 awards will be presented in recognition of the best poster research presentations during the conference. All poster research presentations will be judged by a BHIVA-appointed poster research judging panel. A rosette will be awarded to the top 15 posters at 1830 on Thursday 6 April. The awards will be acknowledged during the Prizes and Awards Ceremony on Friday 7 April.

Mediscript Awards in collaboration with BHIVA

Two prizes will be awarded for the best oral or poster research presentation during the conference in the field of social sciences and community-based work. The awards will be presented at the Prizes and Awards Ceremony on Friday 7 April.

BHIVA Science Scholarships

Science Scholarships have been awarded to 10 researchers and scientists whose abstracts have been accepted for presentation. All registration fees and accommodation for up to three nights are covered by BHIVA.

BHIVA Junior Registration Scholarships

BHIVA have supported 30 registration scholarships for UK-based non-consultant healthcare professionals who work in the field of HIV medicine. Applications were invited from junior doctors, Nurses (band 1–4), junior pharmacists and non-clinical junior researchers to attend the Conference. The scholarship covers a delegate's conference registration free.

BHIVA Community Registration Support

BHIVA have supported over 50 registration places from community and affiliated organisations in order to assist with attendance at conference.

BHIVA Community Scholarships

BHIVA Community Scholarships have been awarded to up to 10 UK-based community registrants. All registration fees and accommodation for up to three nights have been covered by BHIVA. In addition a contribution is offered by BHIVA towards travel expenses.

BHIVA Registration Scholarships

Registration Scholarships have been awarded to up to 10 delegates who are either retired, not working or employed in a part-time capacity. Places are also allocated to students involved in full-time undergraduate or post-graduate work. The scholarship covers the conference registration fee.

BHIVA Registration Scholarships in collaboration with ViiV Healthcare UK

ViiV Healthcare in collaboration with the British HIV Association (BHIVA) have supported over 50 registration scholarships to assist healthcare professionals (BHIVA members) to attend the 23rd Annual BHIVA Conference. Applications have been reviewed by BHIVA and have been allocated on an assessment of merit. ViiV Healthcare UK have had no involvement in the selection of scholarship winners

SOCIAL EVENTS

Welcome Reception

ACC Liverpool

Wednesday 5 April 2017: 1830–1930

ACC Liverpool is a uniquely flexible venue, the only directly interconnected arena and convention centre in Europe. ACC Liverpool opened its doors for the first time as the city celebrated European Capital of Culture. Since this time a string of accolades have followed, including CONFEX's coveted 'Best UK Venue' for two consecutive years, 'Best Corporate Social Responsibility Initiative' and 'Most Effective Team' at the Exhibition News awards. The venue has hosted international events ranging from the MTV Europe Music Awards and the British Council of Shopping Centres' annual conference to the BBC Sports Personality of the Year.

The Welcome Reception will begin with some short speeches in the exhibition area (Hall 2A) followed by an opportunity for delegates to network whilst enjoying a drink and some light refreshments.



Programme of events

- 1830–1850 Drinks and Canapés
- 1850–1905 Speeches
- 1905–1930 Drinks and Canapés
- 1930 Close

Gala Dinner

*Ticket required**Dress code: Gentlemen are requested to wear jacket and tie*

The Venue at the Royal Liver Building

Thursday 6 April 2017: 1945–0030

Overlooking the River Mersey and dominating one of the world's most famous waterfront skylines, is the Royal Liver Building. This iconic symbol of Liverpool, built in 1911, and at the time, the tallest building in Europe, has the enviable status of a Grade 1 listed landmark building. Classic on the outside yet modern, light and chic on the inside with large open-plan interiors that push the boundaries of contemporary design and technology.

The Gala Dinner will commence with a drinks reception followed by dinner in the Bertie Suite. After some short speeches, entertainment will be provided by Drag DJ, Dixie Tucker.



Programme of events

- Drinks reception
- Dinner
- Speeches
- Entertainment, music and dancing

PLENARY SPEAKER BIOGRAPHIES

Alejandro Arenas-Pinto is a Senior Clinical Research Associate in the UCL Research Department of Infection and Population Health and MRC Clinical Trials Unit at UCL. Trained in Infectious Diseases and Tropical Medicine in Venezuela and in the UK. He completed his PhD in 2006 at UCL. Since 2007 he has been involved in a number of national and international randomised clinical trials on HIV treatment. Currently, Alejandro is Chief Investigator for the START trial and all substudies in the UK as well as Medical Officer for the London ICC and protocol team member.

David Back is Professor (Emeritus) of Pharmacology at the University of Liverpool and has been at the forefront of studies on PK and drug–drug interactions of ARVs and drugs for treatment of Hepatitis C. David has authored ~450 publications. He is a former Editor in chief of the British Journal of Clinical Pharmacology. He has established key resources for health care professionals including www.hiv-druginteractions.org and www.hep-druginteractions.org. In 2007 he was awarded the Lilly Prize from the British Pharmacological Society for outstanding contribution to Clinical Pharmacology and in 2015 a Lifetime achievement award from EACS.

J S Bamrah is an Elected member and Director of BMA Council, and National Chairman of BAPIO. He is Honorary Reader at the University of Manchester and Professor of Psychiatry at Bhatinda College for Nursing, India. He is past Medical Director of Manchester Mental Health and Social Care Trust and Governing Body member of Tameside & Glossop CCG, and was an Executive Director of Manchester Academic and Health Science Centre from 2013-2016. He has held senior positions in the BMA and the Royal College of Psychiatrists for over two decades. JS, as he is popularly known as, has had a keen interest in the NHS, governance, clinical management, development of services, diversity, education and training.

Tristan Barber is currently working as a consultant in sexual health and HIV at Chelsea and Westminster Hospital. He has a research background in HIV related neurocognitive impairment. Tristan is currently chair of the BHIVA International Working Group and the BASHH HIV Specialist Interest Group.

Simon Barton Consultant Physician in HIV/ Genitourinary Medicine since 1990 and was appointed Trust Associate Medical Director for Integrated Healthcare in 2014. From 1996 to 2014 he was Clinical Director of HIV and Sexual Health, Dermatology and Pathology Directorate at Chelsea & Westminster Hospital, London, UK. He was the Clinical Advisor on Sexual Health for the London Sexual Health Programme, and was President of the British Association for Sexual Health & HIV (BASHH) from 2006-2008. He is actively involved in educational and training issues in sexual health, being the UK representative to the European Union of Medical Specialists. He was appointed as the Chair of the HIV Clinical Reference Group 2012-15 to lead the HIV specialist advice to NHS Commissioning Board. In 2015 he was appointed as Clinical Chair of the Blood and Infection Programme of Care Board of NHS England.

Christoph Boesecke MD completed his medical studies at Charité University in Berlin, Germany. He received his Doctorate in Medicine from the University of Hamburg, Germany for his research in acute HIV infection. He held a 2-year postgraduate position studying integrase inhibitors in acute and chronic HIV infection at the National Centre in HIV Epidemiology and Clinical Research (now The Kirby Institute) in Sydney, Australia. He is currently working as an Infectious Diseases Specialist and Clinical Research Fellow at the University of Bonn, Germany. His main areas of research are focused on co-morbidities and co-infections in HIV, particularly acute Hepatitis.

David Chadwick is an ID Physician in Middlesbrough who has worked in HIV for 20 years, with research interests in HIV and viral hepatitis coinfection in Africa, and HIV testing in the UK. David has contributed to BHIVA through the Immunisation guidelines and HIV-2 committees, CROI feedback sessions, the UK CHIC Executive Committee and Diploma in HIV Medicine question setting.

Valerie Delpech is a Medical Epidemiologist based at Public Health England and leads a team of scientists and data managers to monitor the HIV epidemic and quality of care people living with HIV receive in the United Kingdom. Valerie's research interests focus on better understanding the epidemiology of HIV and STIs, and public health interventions to prevent these infections particularly among vulnerable populations. She serves on a number of national and international committees in relation to HIV public health monitoring, prevention and policy development and is an executive trustee for the National AIDS Trust.

Monica Desai is a Consultant Medical Epidemiologist at Public Health England. She is one of the lead Consultants for the PrEP IMPACT trial. She also leads a group of scientists and data managers in the blood borne virus section of the HIV & STI Department to monitor infections among people who inject drugs, and surveillance of blood borne virus infections in healthcare workers.

PLENARY SPEAKER BIOGRAPHIES

John Frater is an MRC Senior Clinical Fellow and Honorary Consultant Physician in Infectious Diseases. His research group is interested in HIV persistence, the latent reservoir and strategies for an HIV cure.

Anna Maria Geretti, MD, PhD, FRCPath, is Professor of Virology & Infectious Diseases at the Institute of Infection & Global Health, University of Liverpool, and Honorary Consultant in Infectious Disease at the Royal Liverpool University Hospital. She trained in Italy, the Netherlands and the United Kingdom. Her clinical and research work specialises in antiviral therapy, virus genetic diversity, and viral diagnostics, has a focus on HIV and viral hepatitis, and has led to over 200 publications. She contributes to policy formulation internationally and enthusiastically shares her expertise to train healthcare professionals and scientists. In March 2017, Anna Maria started work as Expert Scientist in the Pharma Research & Early Development group of Hoffmann-La Roche, with the objective of researching hepatitis B therapies.

Phillip Gothard is a Consultant in Infectious Diseases at the Hospital for Tropical Diseases in London and Senior Lecturer at the London School of Hygiene and Tropical Medicine.

John Green is Chief Clinical Psychologist CNWL NHS FT and Consultant Clinical Psychologist in Sexual Health working clinically in the GUM services at St Mary's Hospital Paddington. He is also Clinical Director for CNWL's IAPT services. CNWL is the largest NHS provider nationally of IAPT services, a national programme which provides primary care facing services for people with anxiety and depression. He has a long standing interest in psychological factors in HIV infection.

Andrew Hill graduated from Oxford University, and then worked on HIV at St Mary's Hospital in London. He is a Senior Visiting Research Fellow at Liverpool University. He is also an advisor to the World Health Organisation and the Clinton Foundation on HIV and other diseases.

Paul Holmes is a Consultant Neurologist at Guy's & St. Thomas' Hospitals and Honorary Senior Lecturer at King's College Hospital. His main work is in providing an acute liaison neurology service, with particular interest in stroke, intensive care neurology, headache and the neurology of HIV infection. He trained at the University of Witwatersrand, Johannesburg, and came to the UK in 1991, where he completed his specialist training in neurology at Guys & St. Thomas', King's and the National Hospital for Neurology & Neurosurgery, Queen Square. He obtained an MD in TIA and stroke imaging at the University of London in 2000.

Richard Jones is the Clinical Director of the Practitioner Health Programme, a specialist service for sick doctors and dentists with mental health and addiction problems (www.php.nhs.uk).

Saye Khoo is Professor in the Institute of Translational Medicine at the University of Liverpool, and Consultant Physician in Infectious Diseases at the Royal Liverpool University Hospital. He also leads an active research programme in therapeutics of HIV, TB and HCV. The primary research focus is on good prescribing and personalised treatment: this includes treatment optimisation in special populations (e.g. very young children, pregnant women, liver and kidney impairment), sterilisation of HIV within tissue compartments, drug interactions, and HIV prevention. This research is funded by the Wellcome Trust, the Medical Research Council, the US National Institute of Health, NIHR, EPSRC, UNITAID, EDCTP and the pharmaceutical industry. Two web-based prescribing support tools for managing drug interactions (www.hiv-druginteractions.org and www.hep-druginteractions.org) and accompanying smartphone Apps (HIV iCharts and Hep iCharts) are widely utilised in clinical practice.

Margaret Kingston has been a Consultant in Central Manchester since 2003, and in 2006 co-founded the St Mary's HIV antenatal service which provides specialist MDT care for HIV positive women and their babies in Manchester.

Fiona Lampe is Senior Lecturer in Epidemiology and Biostatistics, in the Research Department of Infection and Population Health, University College London. Her main areas of work are HIV-related observational studies and clinical trials. Her research interests include: HIV treatment and prognosis; the impact of gender, region, and socio-economic status on HIV treatment outcomes; mental health and quality of life; HIV prevention. She is primary investigator of a number of research studies in the fields of HIV health, clinical care and prevention, including the ASTRA Study.

Clifford Leen is a consultant physician in Infectious Diseases and HIV at the Western General Hospital Edinburgh and Honorary Professor of Infectious Diseases at the University of Edinburgh. He now leads a research unit involved in international and national studies on the treatment of HIV and hepatitis C and was the Secretary of the BHIVA Hepatitis Working Group Executive Panel. He has been on the BHIVA Treatment Guidelines Writing Committee since 2003, and the BHIVA hepatitis guidelines. He chaired the BHIVA Education and Scientific Subcommittee from 2008 to 2011, and has been a member of the management group of Edinburgh University's Centre for Infectious Diseases since 2008.

PLENARY SPEAKER BIOGRAPHIES

Emily Lord is an ST6 trainee from Oxford. During her training she was for 2 years the trainee representative to both the BASSH board and the JRCPTB Specialist Advisory Committee. Her involvement in BASHH has continued, and she is now the treasurer for the Oxford BASHH regional meetings. She is currently on the writing committee for the BHIVA/BASHH/FSRH guideline on management of sexual and reproductive health of people living with HIV infection.

Nicky Mackie is a Consultant Physician and Head of Speciality for HIV at Imperial College Healthcare NHS Trust. Her research was in the field of HIV-1 drug resistance and she runs the weekly Virtual Clinic. She is also the Clinical Lead for the HIV Womens' Service at Imperial. She is involved with writing national guidelines, examining for dipHIV and teaching for BASHH and EACS. She has recently been elected as a Trustee member of the BHIVA Executive Committee.

Ula Mahadeva is a Consultant Histopathologist at Guy's and St Thomas' NHS Foundation Trust where her areas of subspecialisation are gastrointestinal histopathology, gynaecological and non-gynaecological cytopathology, consented and maternal death autopsies, and infectious disease histopathology. She is known within the department and region for her enthusiasm for teaching and training, including helping trainees with preparation for the FRCPath examination, and is an RCPATH examiner.

Alastair Miller first saw HIV patients as a trainee in the 1980s and has been involved in their clinical care, research and teaching ever since. He was on the BHIVA executive for several years and chaired the conference committee that brought the last BHIVA conference to Liverpool where he was also local host. He retired from infectious disease practice in Liverpool in 2016 and now works a day a week as an acute physician in Carlisle and is Deputy Medical Director of the Joint Royal Colleges of Physicians Training Board (JRCPTB) where he chairs the Internal Medicine Committee that is designing the new curriculum. He trained in Medicine at Cambridge & Westminster and did his ID training in Birmingham and London.

Rak Nandwani is a Consultant in Glasgow. He chairs the Scottish HIV Clinical Leads and was chair of the PrEP short-life working group for Scotland. He also chairs the Specialty Advisory Committee which is responsible for GUM training in the UK. Rak was previously involved in development of Scotland's sexual health strategy, as Clinical Adviser for the sexual health services standards and as the CMO's specialty adviser 2004-10. Rak is also the Lead Clinician for the west of Scotland sexual health Managed Clinical Network. He jointly led the establishment of Sandyford services in 2000 and was Acting Director 2010-2012, designing the new curriculum. He trained in Medicine at Cambridge & Westminster and did his ID training in Birmingham and London.

Nneka Nwokolo is a Consultant in Sexual Health and HIV Medicine at 56 Dean Street, Chelsea and Westminster Hospital. She was the Chair of the Writing Group for the 2015 BASHH national Chlamydia treatment guideline. Her special interests include the sexual and reproductive health of HIV positive women, particularly with regard to contraception and the menopause, as well as the application of new molecular techniques to facilitate the rapid diagnosis of bacterial and viral infections, reducing time to treatment and onward transmission of infections. She has a particular interest in HIV pre-exposure prophylaxis and established the first PrEP clinic in the UK.

Chloe Orkin is Chair of the British HIV Association and Consultant Physician at the Royal London Hospital where her clinical duties include running a busy HIV and HIV/ HCV research unit. Her specialist interests are: Anti-retroviral therapy, hepatitis and oncology. She has 90 peer-reviewed publications and has co-authored four British HIV Association guidelines on: Anti-retroviral therapy, Hepatitis, Malignancy and Routine Monitoring. Professor Orkin is the External Examiner to the Diploma in HIV Medicine. She is actively researching ways of implementing HIV and blood-borne virus testing.

Matthew Page is an SpR in GU/HIV Medicine, undertaking a one year research post as his Out Of Programme Experience (OOPE) from his specialist training. He is currently working at Birmingham Heartlands HIV Service to take lead on several trials, including the DISCOVER trial (PrEP trial in MSM and TGW) and FLAIR (long-acting injectable ARVs) trial. He is the DIT representative for the MSM SIG for BASHH, and a volunteer for the Saving Lives UK HIV charity. He has been involved with radio interviews and social media Q&A sessions on topics about HIV testing and sexual health.

Sarah Pett is a Senior Clinical Lecturer in Infectious Diseases, University College London (UCL) Research Department of Infection and Population Health (IPH) and Medical Research Council Clinical Trials Unit (MRC CTU) at UCL since 2013; Honorary Consultant Physician, CNWL and Visiting Associate Professor, Faculty of Medicine, University of New South Wales, Australia. She has been involved with the development, coordination and successful completion of several international multicentre Phase III and IV randomised interventional studies in HIV and influenza through the INSIGHT, Kirby Institute and MRC CTU research networks.

PLENARY SPEAKER BIOGRAPHIES

Matt Phillips is a consultant in Genitourinary Medicine and Clinical Director for Sexual Health Services in Cumbria Partnership NHS Foundation Trust. After completing a masters in law at Keele in 2007, he has continued to contribute to the field of HIV transmission and the law in various guises including the BHIVA position statement, the Law Commissioner's consultation on the Offences Against the Persons Act in 2014 and most recently collaborative work with the Law School at Newcastle University. He has an MD in Pharmacology and Therapeutics from Trinity College Dublin.

Lene Ryom MD, PhD, CHIP, centre of excellence for health, immunity and infections, Rigshospitalet, Copenhagen, Denmark. Co-Principal investigator of the D:A:D study. Assistant Coordinator of the EACS Guidelines.

Suneeta Soni has been a Consultant in Sexual Health and HIV in Brighton since 2010. Her current clinical and research interests are the testing and treatment of Mycoplasma genitalium and STI and HIV testing in men who have sex with men. She is a core member of the BASHH Bacterial Special Interest Group and chairs the medical advisory board for sexual health charity NAZ.

Ann Sullivan is a Consultant Physician and Clinical Lead for the HIV Out-Patient Department at Chelsea and Westminster Hospital and Honorary Senior Lecturer, Imperial College, London. She trained in Hobart, Sydney and London and obtained her MD for her thesis: 'Immune reconstitution in HIV-1 infection: the effects of antiretroviral and immune therapy'. She has been involved in a number of HIV testing and prevention research studies, and is currently involved in OptTEST, a European-wide indicator condition-guided HIV testing project, and BEDS, a local blood-borne virus Emergency Department based opt out testing programme. She has been involved in the development, writing and evaluation of a number of HIV testing guidelines both Nationally and Internationally. Dr Sullivan was elected as BHIVA Honorary Secretary in 2016 and is Vice Chair of the Audit and Standards subgroup.

Steve Taylor is the Lead Consultant for Birmingham Heartlands HIV Service, Honorary Senior Clinical Lecturer at the University of Birmingham, Tri-Service Consultant Advisor to HM Armed Forces, and Medical Director of the National Saving Lives Charity. He is on the BHIVA Executive committee and an active member of the National NHSE HIV CRG Antiretroviral Sub-group. He is the Research Lead for the Birmingham Heartlands HIV Service and Primary Investigator on numerous on going HIV/Hepatitis clinical trials. His research interests are in the efficacy and Clinical Pharmacology of HIV/Hepatitis Antiviral therapy, Sexual Transmission of HIV, and Testing Strategies for HIV and Viral Hepatitis.

Melinda Tenant-Flowers retired as Consultant in HIV/Sexual Health, King's College Hospital, London in 2015. Her research interests included HIV oncology, HIV testing and educational assessment. She contributed to the BHIVA Guidelines for Malignancy (2014) Monitoring (2015) and PrEP (2017). She has an MSc in Medical Education, is lead for BHIVA E-Learning CPD and a member of the BHIVA Education/Scientific, Conferences and Website Subcommittees. She is an examiner for the Diplomas in HIV and GU Medicine, was Convenor of the Diploma in GU Medicine, STC co-chair and ARCP/PYA representative (London) and contributed to the 2016 HIV curriculum for the SAC/RCP.

Emma Thomson is a clinical senior lecturer and consultant in infectious diseases and runs the HIV/HCV coinfection service in Glasgow. She runs a research laboratory that is focussed on understanding the immune response to early infection with hepatitis C using next generation sequencing and T cell assays. She is a member of the WHO guidelines development group for hepatitis C.

Laura Waters is a Consultant at the Mortimer Market Centre in London where she is HIV and Hepatitis Service Lead and principal investigator for several antiretroviral trials. She was Vice-Chair of the 2015 BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy and now chairs this group. She is Chair of the BHIVA Conferences subcommittee and previous Chair of the BASHH HIV Special Interest Group. She is BASHH rep on the HIV CRG, vice-chair HIV London leads group and a THT trustee.

Gareth Tudor-Williams MD is a Reader in Pediatric Infectious Diseases at Imperial College London and Consultant Paediatrician at Imperial College Healthcare NHS Trust, St. Mary's Hospital, London. His interest in pediatric infectious diseases was sparked by two years working in the Himalayas for Save the Children Fund UK. He has specialised in HIV infection in children since 1989, as a Fellow at Duke University, N. Carolina (with Prof. Cathy Wilfert), and as a Visiting Scientist / Attending Physician at the National Institutes of Health, Bethesda, MD (with Prof. Phil Pizzo). Since 1994 he has helped run a multi-disciplinary service for HIV infected children and their families at St. Mary's Hospital, London. Academic roles: founding Chairman of the Children's HIV Association of the UK and Ireland (CHIVA). Involved in clinical trials with the Pediatric European Network for the Treatment of AIDS (PENTA). Co-principal investigator for the PENTA/IMPACT study - PENPACT 1. Chair of the End-point Review Committee for the ARROW trial of 1200 HIV-infected children (Uganda / Zimbabwe). Helped establish the CHIVA-Africa initiative, supporting the roll-out of antiretrovirals for children in S. Africa. Trustee of the UK Thailand Children's Fund, supporting HIV affected children in northern Thailand.

Andrew Ustianowski is a consultant physician in Infectious Diseases and research lead at the North Western Regional Infection Unit, North Manchester General Hospital, UK, which is one of the largest treatment centres for blood-borne viruses in the UK. He has been chair of the British Viral Hepatitis Group, part of guideline writing committees for the British HIV Association & other bodies, lectures widely on HIV, hepatitis & related topics, and is part of several national and international educational steering groups. He graduated from Guy's Hospital, London, and subsequently trained in Infectious Diseases, Tropical Medicine, HIV and General Medicine in the London region.

Martin Wiselka is a Consultant Physician and Honorary Professor of Infectious Diseases in the Department of Infection and Tropical Medicine at University Hospitals of Leicester. After graduating from Oxford University he trained in Oxford, Nottingham and Manchester, before coming to Leicester as a Wellcome Training Fellow and his appointment as Consultant in Infectious Diseases. He was awarded an Honorary Professorship by the University of Leicester in 2015. Professor Wiselka's particular interests include TB, and blood-borne virus infections. He is the Lead for the Leicester Hepatitis C Operational Delivery Network. He has been a member of the British HIV Association Executive Committee and NICE TB Guidelines Committee. He is currently President of the British Infection Association, Chairs the RCP SAC for Infectious Diseases and has been a part of the question writing and standard-setting committees for the SCE in ID and the new Combined Infection Certificate Examination

FORTHCOMING EVENTS

BHIVA Hepatology Highlights for the Healthcare Specialist in collaboration with BVHG

Thursday 11 May 2017

Post EASL feedback meeting
Radisson Blu Hotel, Birmingham

Wednesday 15 November 2017

Post AASLD feedback meeting
Venue TBC, London

BHIVA General Medicine Course

Thursday 12 October 2017

NCVO London

BHIVA Autumn Conference

16–17 November 2017

London

Joint BHIVA/BASHH Diploma in HIV Medicine One-Day Revision Course

Monday 4 September 2017

South Wing Lecture Theatre
St Thomas' Hospital, London

BHIVA World AIDS Day Event

November / December 2017 (date tbc)

London

21st Annual Antiviral Therapy and Drug Resistance Meeting

Thursday 21 September 2017

Wellcome Collection, London

SPONSORS AND EXHIBITORS

BHIVA MAJOR SPONSORS 2017

Gilead Sciences Ltd

280 High Holborn,
London
WC1V 7EE



Janssen

50–100 Holmers Farm Way,
High Wycombe
Buckinghamshire HP12 4DP



MSD Ltd

Hertford Road,
Hoddesdon
Hertfordshire EN11 9BU



ViiV Healthcare UK Ltd

Stockley Park West,
Uxbridge
Middlesex UB11 1BT



BHIVA is grateful to their major sponsors and commercial exhibitors for their continued support. The funds provided by sponsors are used solely for the educational content of the conference and are not allocated to BHIVA's social events.

Conference Organiser: Mediscript Ltd,
1 Mountview Court,
310 Friern Barnet Lane, London N20 0LD
T: +44 (0) 20 8369 5380 F: +44 (0)20 8446 9194
E: conferences@bhiva.org

EXHIBITORS

Commercial

Cepheid

Idox Health

Kora Healthcare

Oxford Immunotec

Affiliated, Educational and Charitable

Children's HIV Association (CHIVA)

Dietitians in HIV/ AIDS (DHIVA)

HIV Pharmacy Association (HIVPA)

HIV Trainees Club

Mildmay Mission Hospital

Rehabilitation in HIV Association (RHIVA)

Saving Lives

Community

African Health Policy Network

Body and Soul

George House Trust

HIV i-Base

NAM

National AIDS Trust

Positively UK

Sahir House

The Sophia Forum

The Sussex Beacon

Terrence Higgins Trust

UK Community Advisory Board (UK-CAB)

DESCOVY® PRESCRIBING INFORMATION

Consult the Summary of Product Characteristics (SPC) before prescribing. **Descovy® ▼ emtricitabine 200mg/tenofovir alafenamide 10mg or 25mg film-coated tablets.** **Indication:** In combination with other antiretroviral agents for the treatment of HIV-1 infection in adults & adolescents (aged 12 years & older weighing at least 35 kg). **Dosage:** Adults & adolescents (aged ≥ 12 years, weighing at least 35 kg): One tablet, once daily, orally with or without food. The dose of Descovy should be administered according to the third agent in the HIV treatment regimen. Please consult the SPC for further information. Children (< 12 years or weighing < 35 kg): Safety & efficacy has not been established. Elderly: No dose adjustment is required. Renal: No dose adjustment is required in adult or adolescent patients (aged ≥ 12 years, weighing at least 35 kg) with estimated creatinine clearance (CrCl) ≥ 30 mL/min. In patients with CrCl < 30 mL/min: not recommended. Should be discontinued in patients whose CrCl declines to < 30 mL/min during treatment. Hepatic: Mild/moderate hepatic impairment: no dose adjustment required. Severe hepatic impairment: not recommended. **Contraindications:** Hypersensitivity to the active substances or to any excipients. **Warnings & Precautions:** Safety &

efficacy in HBV/HCV co-infection has not been established. Co-infected HIV/HBV patients should be closely monitored for at least several months following discontinuation for symptoms of severe acute exacerbations of hepatitis. Descovy should be avoided in antiretroviral patients with HIV-1 harbouring the K65R mutation. Risks of mitochondrial dysfunction, immune reactivation syndrome, opportunistic infections, osteonecrosis with CART therapy. **Interactions:** Co-administration with certain anticonvulsants (e.g. carbamazepine, oxcarbazepine, phenobarbital & phenytoin), antimycobacterials (e.g. rifampicin, rifabutin & rifapentine), boceprevir, telaprevir, St. John's wort and HIV PIs other than atazanavir, lopinavir and darunavir is not recommended. Should not be administered concomitantly with medicines containing tenofovir disoproxil (as fumarate), lamivudine or adefovir dipivoxil. Co-administration of emtricitabine with medicinal products that are eliminated by active tubular secretion may increase concentrations of emtricitabine. Medicinal products that decrease renal function may increase concentrations of emtricitabine. Medicinal products that induce P-glycoprotein (P-gp) are expected to decrease the absorption of tenofovir alafenamide, resulting in decreased plasma concentration of tenofovir alafenamide, which may

lead to loss of therapeutic effect of Descovy and development of resistance. Co-administration with medicinal products that inhibit P-gp are expected to increase the absorption and plasma concentration of tenofovir alafenamide. Tenofovir alafenamide is a substrate of OATP1B1 and OATP1B3 *in vitro*. The distribution of tenofovir alafenamide in the body may be affected by the activity of OATP1B1 and OATP1B3. **Pregnancy & lactation:** Use in pregnancy only if potential benefit justifies the potential risk to the foetus. Breast-feeding; not recommended. **Side effects:** Refer to SPC for full information regarding side effects. Very common (≥1/10): Nausea. Common (≥1/100 to <1/10): Headache, dizziness, diarrhoea, vomiting, abdominal pain, flatulence, abnormal dreams, rash & fatigue. Uncommon (≥1/1000 to <1/100): anaemia, arthralgia, dyspepsia, angioedema & pruritus. **Legal Category:** POM. **Pack:** Bottle of 30 film-coated tablets. **Price:** UK NHS List Price - £355.73; Eire/Ireland - €587.98. **Marketing Authorisation Number:** EU/1/16/1099/001; EU/1/16/1099/003.

Further information is available from Gilead Sciences Ltd, 280 High Holborn, London, WC1V 7EE, UK; Telephone: +44 (0) 8000 113700, For Ireland: +353 214 825 999. E-mail: ukmedinfo@gilead.com. Descovy is a trademark. **Date of approval:** June 2016; FTA/UK/16-03/MM/1052(1).

GENVOYA® PRESCRIBING INFORMATION

Consult the Summary of Product Characteristics before prescribing. **GENVOYA® ▼ elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/ tenofovir alafenamide 10mg film-coated tablets.** **Indication:** Treatment of HIV-1 infection in adults & adolescents (aged 12 years & older weighing at least 35 kg) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir. **Dosage:** Adults & adolescents (aged ≥ 12 years, weighing at least 35 kg): One tablet, once daily, orally & whole with food. Children (< 12 years or weighing < 35 kg): Safety & efficacy has not been established. Elderly: No dose adjustment is required. Renal: No dose adjustment is required in adult or adolescent patients (aged ≥ 12 years, weighing at least 35 kg) with estimated creatinine clearance (CrCl) ≥ 30 mL/min. In patients with CrCl < 30 mL/min: not recommended. Should be discontinued in patients whose CrCl declines to < 30 mL/min during treatment. Hepatic: Mild/moderate hepatic impairment: no dose adjustment required. Severe hepatic impairment: not recommended. **Contraindications:** Hypersensitivity to the active substances or to any excipients. Co-administration with alfuizosin, amiodarone, quinidine, carbamazepine, phenobarbital, phenytoin, rifampicin, dihydroergotamine, ergometrine,

ergotamine, cisapride, St. John's wort, lovastatin, simvastatin, pimozide, sildenafil for treatment of pulmonary arterial hypertension & oral midazolam & triazolam. **Warnings & Precautions:** Should not be co-administered with other antiretroviral products. Safety & efficacy in HBV/HCV co-infection has not been established. Co-infected HIV/HBV patients should be closely monitored for at least several months following discontinuation for symptoms of severe acute exacerbations of hepatitis. Should not be administered concomitantly with medicines containing tenofovir disoproxil (as fumarate), lamivudine or adefovir for treatment of HBV infection. Patients with galactose intolerance, Lapp lactase deficiency & glucose-galactose malabsorption should not take Genvoya. Women of childbearing potential should use either a hormonal contraceptive containing at least 30 µg ethinylestradiol & norgestimate as the progestagen or an alternative reliable method of contraception. Risks of mitochondrial dysfunction, immune reactivation syndrome, opportunistic infections, osteonecrosis with nucleoside analogues & CART therapy. **Interactions:** Co-administration with medicines that induce/inhibit CYP3A may affect the exposure of elvitegravir by decreasing its plasma concentrations leading to a reduced therapeutic effect of Genvoya. Cobicistat is an inhibitor of CYP3A & is a CYP3A substrate. Medicines highly dependent

on CYP3A metabolism & have high first pass metabolism are most susceptible to large increases in exposure when co-administered with cobicistat. Medicines that inhibit CYP3A may decrease the clearance of cobicistat, resulting in increased plasma concentrations of cobicistat. Co-administration with medicines that are substrates of P-gp, BCRP, OATP1B1 & OATP1B3 may result in increased plasma concentrations of these products. Medicines that decrease renal function may increase concentrations of emtricitabine. **Pregnancy & lactation:** Should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. It should not be used during breast-feeding. **Side effects:** Refer to SPC for full information regarding side effects. Very common (≥1/10): Nausea. Common (≥1/100 to <1/10): Headache, dizziness, diarrhoea, vomiting, abdominal pain, flatulence, abnormal dreams, rash & fatigue. Uncommon (≥1/1000 to <1/100): anaemia, depression, dyspepsia, angioedema & pruritus. **Legal Category:** POM. **Pack:** Bottle of 30 film-coated tablets. **Price:** UK NHS List Price - £879.51; Eire/Ireland - €1266.00. **Marketing Authorisation Number:** EU/1/15/1061/001.

Further information is available from Gilead Sciences Ltd, 280 High Holborn, London, WC1V 7EE, UK; Telephone: +44 (0) 8000 113700. E-mail: ukmedinfo@gilead.com, Genvoya is a trademark. **Date of approval:** July 2016. Job Bag No: TAF/UK/15-09/MM/1098(1).

ODEFSEY® PRESCRIBING INFORMATION

Consult the Summary of Product Characteristics (SPC) before prescribing. **Odefsey® ▼ emtricitabine 200mg/ rilpivirine 25mg/ tenofovir alafenamide 25mg film-coated tablets.** **Indication:** Treatment of HIV-1 infection in adults & adolescents (aged 12 years & older weighing at least 35 kg) without any known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV-1 RNA copies/mL. **Dosage:** Adults & adolescents (aged ≥ 12 years, weighing at least 35 kg): One tablet, once daily, orally with food. Children (< 12 years or weighing < 35 kg): Safety & efficacy has not been established. Elderly: No dose adjustment is required. Renal: No dose adjustment is required in adult or adolescent patients (aged ≥ 12 years, weighing at least 35 kg) with estimated creatinine clearance (CrCl) ≥ 30 mL/min. In patients with CrCl < 30 mL/min: not recommended. Should be discontinued in patients whose CrCl declines to < 30 mL/min during treatment. Hepatic: Mild/moderate hepatic impairment: no dose adjustment required. Use with caution in patients with moderate hepatic impairment. Severe hepatic impairment: not recommended. **Contraindications:** Hypersensitivity to the active substances or to any excipients. It should not be co-administered with medicines that can result in significant decreases in rilpivirine plasma concentrations (due to cytochrome P450 [CYP3A] enzyme induction or gastric pH increase), which may result in loss of therapeutic effect of Odefsey including: carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampicin, rifapentine, omeprazole, esomeprazole, dexlansoprazole, lansoprazole, pantoprazole, rabeprazole, dexlansoprazole (oral and parenteral doses), except as a single dose treatment,

St. John's wort. **Warnings & Precautions:** There are insufficient data to justify the use in patients with prior NNRTI failure. Resistance testing and/or historical resistance data should guide the use of Odefsey. At supratherapeutic doses (75 mg once daily and 300 mg once daily), rilpivirine has been associated with prolongation of the QTc interval of the electrocardiogram (ECG). Should be used with caution when co-administered with medicines with a known risk of Torsade de Pointes. Safety & efficacy in HBV or HCV co-infection has not been established. Co-infected HIV/HBV patients should be closely monitored with both clinical and laboratory follow up for at least several months following discontinuation for symptoms of severe acute exacerbations of hepatitis. The safety and efficacy of Odefsey in patients with significant underlying liver disorders have not been established. Risks of mitochondrial dysfunction, immune reactivation syndrome, opportunistic infections, osteonecrosis with CART therapy. Should not be co-administered with other antiretroviral medicines or with other medicines containing tenofovir alafenamide, lamivudine, tenofovir disoproxil (as fumarate) or adefovir dipivoxil. **Interactions:** Co-administration of emtricitabine with medicines that are eliminated by active tubular secretion may increase concentrations of emtricitabine and/or the co-administered medicines. Medicines that decrease renal function may increase concentrations of emtricitabine. Rilpivirine is primarily metabolised by CYP3A. Medicines that induce or inhibit CYP3A may thus affect the clearance of rilpivirine. Medicines that induce P-glycoprotein (P-gp) are expected to decrease the absorption of tenofovir alafenamide, resulting in decreased plasma concentration of tenofovir alafenamide, which may lead to loss of therapeutic effect of Odefsey and

development of resistance. Co-administration with medicines that inhibit P-gp are expected to increase the absorption and plasma concentration of tenofovir alafenamide. Tenofovir alafenamide is a substrate of OATP1B1 and OATP1B3 *in vitro*. The distribution of tenofovir alafenamide in the body may be affected by the activity of OATP1B1 and OATP1B3. **Pregnancy & lactation:** Use in pregnancy only if potential benefit justifies the potential risk to the foetus. Breast-feeding; not recommended. **Side effects:** Refer to SPC for full information regarding side effects. Very common (≥1/10): increased total cholesterol (fasted), increased LDL cholesterol (fasted), insomnia, headache, dizziness, nausea, increased pancreatic amylase, increased transaminases (AST and/or ALT). Common (≥1/100 to <1/10): decreased white blood cell count, decreased haemoglobin, decreased platelet count, decreased appetite, increased triglycerides (fasted), depression, abnormal dreams, sleep disorders, depressed mood, somnolence, abdominal pain, vomiting, increased lipase, abdominal discomfort, dry mouth, flatulence, diarrhoea, increased bilirubin, rash, fatigue. Uncommon (≥1/1000 to <1/100): anaemia, immune reactivation syndrome, dyspepsia, severe skin reactions with systemic symptoms, angioedema, pruritus, arthralgia. **Legal Category:** POM. **Pack:** Bottle of 30 film-coated tablets. **Price:** UK NHS List Price - £525.95; Eire/Ireland - TBC. **Marketing Authorisation Number:** EU/1/16/1112/001; EU/1/16/1112/002. Further information is available from Gilead Sciences Ltd, 280 High Holborn, London, WC1V 7EE, UK; Telephone: +44 (0) 8000 113700, For Ireland: +353 214 825 999. E-mail: ukmedinfo@gilead.com. Odefsey is a trademark. **Date of approval:** June 2016; ODE/UK/16-05/MM/1015.

▼ This medicinal product is currently subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse reactions to Descovy, Genvoya or Odefsey should be reported to Gilead via email to Safety_FC@gilead.com or by telephone +44 (0) 1223 897500.

Adverse events should be reported. For the UK, reporting forms and information can be found at www.yellowcard.mhra.gov.uk

For Ireland, suspected adverse reactions should be reported to the HPRA Pharmacovigilance using a Yellow Card obtained either from the HPRA, or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling +353 1 6764971.

REFERENCES:

1. Data on file - Gilead Sciences Ltd - HIV-UK-16-04. 2. NHS England Clinical Commissioning Policy: Tenofovir Alafenamide for treatment of HIV-1 in adults and adolescents. 16043/P. Available at: https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2013/05/16043_FINAL.pdf. Accessed November 2016. 3. SMC, Emtricitabine/tenofovir alafenamide 200 mg/25 mg, 200 mg/10 mg film-coated tablets (Descovy®). Available at: http://www.scottishmedicines.org.uk/files/advic/emtricitabine_tenofovir_Descovy_Abb_FINAL_July_2016_for_website.pdf. Accessed November 2016. 4. SMC, Elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg film-coated tablet (Genvoya®). Available at: http://www.scottishmedicines.org.uk/files/advic/elvitegravir_Genvoya_FINAL_April_2016_for_website.pdf. Accessed November 2016. 5. SMC, Rilpivirine/emtricitabine/tenofovir alafenamide 200 mg/25 mg/25 mg film-coated tablets (Odefsey®) Available at: http://www.scottishmedicines.org.uk/files/advic/rilpivirine_emtricitabine_Odefsey_Abbreviated_FINAL_Sept_2016_for_website.pdf. Accessed November 2016. 6. AWMMSG. Final Appraisal Recommendation - 2716: emtricitabine/tenofovir alafenamide (Descovy®) 200 mg/10 mg, 200 mg/25 mg film-coated tablets. Available at: <http://www.awmsg.org/awmsgonline/app/appraisalinfo/2771>. Accessed September 2016. 7. AWMMSG. Final Appraisal Recommendation Advice No: 2216 - July 2016 elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®) 150 mg/150 mg/200 mg/10 mg tablets. Available at: <http://www.awmsg.org/awmsgonline/>

app/appraisalinfo/2248. Accessed August 2016. 8. AWMMSG. Final Appraisal Recommendation Advice No: 3316 - November 2016 emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey®) 200 mg/25 mg/25 mg tablets. Available at: <http://www.awmsg.org/awmsgonline/app/appraisalinfo/3031>. Accessed November 2016. 9. SmPC Descovy®. Available at: <https://www.medicines.org.uk/emc/medicine/31764>. Accessed November 2016. 10. SmPC Genvoya®. Available at: <https://www.medicines.org.uk/emc/medicine/31225>. Accessed November 2016. 11. SmPC Odefsey®. Available at: <https://www.medicines.org.uk/emc/medicine/32117>. Accessed November 2016. 12. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). Available at: <https://www.bhiva.org/documents/Guidelines/Treatment/2016/treatment-guidelines-2016-interim-update.pdf>. Accessed November 2016.

ABBREVIATIONS:

AWMSG, All Wales Medicines Strategy Group; BHIVA, British HIV Association; NNRTI, non-nucleoside reverse-transcriptase inhibitor; RNA, ribonucleic acid; SMC, Scottish Medicines Consortium; STR, single-tablet regimen.





Descovy[®]
emtricitabine/tenofovir alafenamide
200/10mg and 200/25mg tablets

**A TAF-BASED
BACKBONE⁹**

**THREE
TAF-BASED
PRODUCTS ARE
NOW REIMBURSED
ACROSS
THE UK¹⁻⁸**



Genvoya[®]
elvitegravir 150mg/cobicistat 150mg/emtricitabine
200mg/tenofovir alafenamide 10mg tablets

**TAF-BASED INTEGRASE
INHIBITOR STR¹⁰**



Odefsey[®]
emtricitabine 200mg/rilpivirine 25mg/
tenofovir alafenamide 25mg tablets

**TAF-BASED STR WITH
A BHIVA-PREFERRED
NNRTI^{11,12}**

Odefsey[®] is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load $\leq 100,000$ HIV-1 RNA copies/mL.¹¹

Descovy[®] is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type-1 (HIV-1).⁹

Genvoya[®] is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.¹⁰

Prescribing information for Odefsey[®], Descovy[®] and Genvoya[®] is available overleaf.